DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
Heller Bridgette P reported acquisition or exercise transactions in this Form 4 filing.
Dexcom Inc. director Bridgette P. Heller received an equity award of 5,575 restricted stock units (RSUs) of common stock. The RSU grant was made on May 28, 2026 at no cash cost to her and is compensation-related, not an open-market purchase. The RSUs will vest 100% on the earlier of the one-year anniversary of the grant date or Dexcom’s 2027 Annual Meeting of Stockholders. After this award, Heller directly holds 30,582 shares of Dexcom common stock.
Osterloh Albert Frederick IV reported acquisition or exercise transactions in this Form 4 filing.
Dexcom Inc. director Albert Frederick Osterloh IV received an equity grant of 1,630 restricted stock units (RSUs) of Dexcom common stock on May 28, 2026. The award was granted at no cash cost as part of compensation, not through an open-market purchase.
All 1,630 RSUs will vest on the earlier of the one-year anniversary of the grant date or Dexcom’s 2027 Annual Meeting of Stockholders. After this grant, Osterloh holds 8,691 unvested RSUs in total, including 7,061 RSUs granted on February 26, 2026 that are scheduled to vest through February 26, 2029.
Driscoll Rimma reported acquisition or exercise transactions in this Form 4 filing.
DexCom Inc. director Rimma Driscoll received a compensation-related stock award. She was granted 5,605 shares of DexCom common stock in the form of restricted stock units at a price of $0.00 per share.
The RSU award was granted on May 28, 2026 and will vest 100% on the earlier of the one-year anniversary of the grant date or the date of DexCom’s 2027 Annual Meeting of Stockholders. Each restricted stock unit represents a contingent right to receive one DexCom common share upon settlement.
After this award, Driscoll directly holds 17,319 DexCom shares, which include 6,941 unvested restricted stock units. Of these unvested units, 5,605 were granted on May 28, 2026 and 1,336 were granted on August 24, 2023, scheduled to vest through August 24, 2026.
Ashley Euan A. reported acquisition or exercise transactions in this Form 4 filing.
Dexcom Inc. director Euan A. Ashley received an equity grant of 5,565 restricted stock units (RSUs) on May 28, 2026. The award carries no purchase price and is structured as stock-based compensation, not an open-market share purchase.
According to the terms, 100% of this RSU award will vest on the earlier of the one-year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. After this grant, Ashley holds 12,731 unvested RSUs in total, including 7,166 RSUs granted on October 24, 2025 that are scheduled to vest in tranches through October 24, 2028.
Collins Richard Alexander reported acquisition or exercise transactions in this Form 4 filing.
DexCom director Richard Alexander Collins reported a new equity award and his current holdings. He received a grant of 5,605 shares of DexCom common stock in the form of restricted stock units at a stated price of $0.00 per share. The RSU award was granted on May 28, 2026 and will vest 100% on the earlier of the one-year anniversary of the grant date or the date of DexCom’s 2027 Annual Meeting of Stockholders. Each restricted stock unit represents a contingent right to receive one share of DexCom common stock upon settlement. Collins also reported indirect ownership of 40,162 DexCom common shares held by the Richard A. Collins Revocable Trust, for which he serves as trustee.
GALA RENEE D reported acquisition or exercise transactions in this Form 4 filing.
Dexcom director Renee D. Gala reported an equity grant of company stock. On May 28, 2026, she received 5,605 shares of Dexcom common stock in the form of restricted stock units (RSUs), a stock-based compensation award with no cash purchase price.
After this grant, Gala’s reported direct holdings total 12,486 shares of common stock, including 9,418 unvested RSUs. Of these unvested RSUs, 5,605 were granted on May 28, 2026 and will vest on the earlier of the one-year anniversary of the grant date or Dexcom’s 2027 Annual Meeting of Stockholders. The remaining 3,813 RSUs were granted on March 6, 2025 and are scheduled to vest through March 6, 2028.
Dexcom, Inc. reported the results of its 2026 Annual Meeting of Stockholders. At the record date, there were 385,872,977 shares of common stock outstanding and entitled to vote, and 336,525,352 shares were present in person or by proxy, establishing a quorum.
Stockholders elected twelve directors to serve until the 2027 annual meeting or earlier departure. They also ratified Deloitte & Touche LLP as Dexcom’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 336,046,596 votes for and 373,544 against. In addition, stockholders approved, on a non-binding advisory basis, the compensation of Dexcom’s named executive officers, with 277,111,475 votes for and 36,664,959 against.
Dexcom Inc. President, CEO, and Director Jacob Steven Leach reported a tax-related share withholding and updated holdings. On this Form 4, 1,451 shares of common stock were withheld at $71.90 per share to satisfy tax obligations tied to net settlement of restricted stock units, and a footnote states this does not represent a sale by him.
After this withholding, Leach directly owned 420,359 Dexcom shares. A separate entry shows 47,296 shares held indirectly as family holdings through the Gregg Family Grandchildren's Trust, where his spouse serves as a trustee. Footnotes also note 145,686 unvested restricted stock units scheduled to vest between March 8, 2027 and March 8, 2029.
Dexcom executive Michael Jon Brown reported a routine tax-related share withholding tied to restricted stock units. On this Form 4, 1,451 shares of common stock were withheld at $71.90 per share to satisfy tax obligations from the net settlement of vested RSUs, and the footnote clarifies this was not an open-market sale.
After the withholding, Brown directly holds 108,053 Dexcom shares, which include 74,753 unvested restricted stock units scheduled to vest in tranches through March 8, 2029.
Dexcom EVP and Chief Financial Officer Sylvain Jereme M reported a routine tax-related share withholding. On May 22, 2026, 1,451 shares of Dexcom common stock were withheld at $71.90 per share to cover tax obligations tied to restricted stock unit settlement, and the footnote clarifies this does not represent a sale.
After this withholding, he directly holds 151,841 shares of common stock, which includes 89,944 unvested restricted stock units. These RSUs were granted in multiple awards between March 8, 2024 and March 8, 2026 and are scheduled to vest through March 8, 2029, indicating a significant ongoing equity-based compensation position.